Finepoint Capital LP Acquires 12,500 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Finepoint Capital LP boosted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 2.0% in the third quarter, Holdings Channel.com reports. The fund owned 650,852 shares of the company’s stock after buying an additional 12,500 shares during the quarter. SpringWorks Therapeutics comprises 1.5% of Finepoint Capital LP’s holdings, making the stock its 7th largest holding. Finepoint Capital LP’s holdings in SpringWorks Therapeutics were worth $20,853,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Duquesne Family Office LLC acquired a new stake in shares of SpringWorks Therapeutics during the second quarter worth $38,475,000. Maverick Capital Ltd. boosted its holdings in SpringWorks Therapeutics by 36.3% during the second quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock worth $97,962,000 after buying an additional 691,894 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of SpringWorks Therapeutics by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock valued at $321,373,000 after acquiring an additional 492,783 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of SpringWorks Therapeutics by 102.5% in the 3rd quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock valued at $29,427,000 after acquiring an additional 464,903 shares during the period. Finally, Jane Street Group LLC boosted its stake in SpringWorks Therapeutics by 254.2% during the 1st quarter. Jane Street Group LLC now owns 580,938 shares of the company’s stock worth $28,594,000 after acquiring an additional 416,942 shares during the last quarter.

SpringWorks Therapeutics Stock Performance

NASDAQ:SWTX opened at $39.39 on Tuesday. The company has a market cap of $2.93 billion, a PE ratio of -10.15 and a beta of 0.79. The stock has a 50-day simple moving average of $32.68 and a 200 day simple moving average of $36.71. SpringWorks Therapeutics, Inc. has a 52-week low of $20.19 and a 52-week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. During the same period last year, the company earned ($1.27) earnings per share. The firm’s revenue was up 4810.0% compared to the same quarter last year. On average, research analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SWTX shares. HC Wainwright cut their target price on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Tuesday, November 12th. Evercore ISI started coverage on SpringWorks Therapeutics in a research note on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 target price for the company. JPMorgan Chase & Co. increased their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Finally, Wedbush reiterated an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, November 18th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $67.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.